Scott E. Woodman, Ph.D. - Publications

2004 Yeshiva University, New York, NY, United States 
Molecular Biology, Animal Physiology Biology

52/75 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2016 Gao J, Shi LZ, Zhao H, Chen J, Xiong L, He Q, Chen T, Roszik J, Bernatchez C, Woodman SE, Chen PL, Hwu P, Allison JP, Futreal A, Wargo JA, et al. Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy. Cell. PMID 27667683 DOI: 10.1016/j.cell.2016.08.069  0.64
2016 Chen PL, Roh W, Reuben A, Cooper ZA, Spencer CN, Prieto PA, Miller JP, Bassett RL, Gopalakrishnan V, Wani K, Petaccia De Macedo M, Austin-Breneman JL, Jiang H, Chang Q, Reddy SM, ... ... Woodman SE, et al. Analysis of immune signatures in longitudinal tumor samples yields insight into biomarkers of response and mechanisms of resistance to immune checkpoint blockade. Cancer Discovery. PMID 27301722 DOI: 10.1158/2159-8290.CD-15-1545  0.64
2016 Yoo JH, Shi DS, Grossmann AH, Sorensen LK, Tong Z, Mleynek TM, Rogers A, Zhu W, Richards JR, Winter JM, Zhu J, Dunn C, Bajji A, Shenderovich M, Mueller AL, ... Woodman SE, et al. ARF6 Is an Actionable Node that Orchestrates Oncogenic GNAQ Signaling in Uveal Melanoma. Cancer Cell. PMID 27265506 DOI: 10.1016/j.ccell.2016.04.015  0.64
2016 Johnson DB, Roszik J, Shoushtari AN, Eroglu Z, Balko J, Higham C, Puzanov I, Patel SP, Sosman JA, Woodman SE. Comparative analysis of the GNAQ, GNA11, SF3B1, and EIF1AX driver mutations in melanoma and across the cancer spectrum. Pigment Cell & Melanoma Research. PMID 27089234 DOI: 10.1111/pcmr.12482  0.64
2016 Roszik J, Wu CJ, Siroy AE, Lazar AJ, Davies MA, Woodman SE, Kwong LN. Somatic Copy Number Alterations at Oncogenic Loci Show Diverse Correlations with Gene Expression. Scientific Reports. 6: 19649. PMID 26787600 DOI: 10.1038/srep19649  0.64
2016 Cooper ZA, Reuben A, Spencer CN, Prieto PA, Austin-Breneman JL, Jiang H, Haymaker C, Gopalakrishnan V, Tetzlaff MT, Frederick DT, Sullivan RJ, Amaria RN, Patel SP, Hwu P, Woodman SE, et al. Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma Oncoimmunology. 5. DOI: 10.1080/2162402X.2015.1136044  0.64
2015 Han L, Diao L, Yu S, Xu X, Li J, Zhang R, Yang Y, Werner HM, Eterovic AK, Yuan Y, Li J, Nair N, Minelli R, Tsang YH, Cheung LW, ... ... Woodman SE, et al. The Genomic Landscape and Clinical Relevance of A-to-I RNA Editing in Human Cancers. Cancer Cell. PMID 26439496 DOI: 10.1016/j.ccell.2015.08.013  0.64
2015 Wilson MA, Zhao F, Khare S, D'Andrea K, Wubbenhorst B, Roszik J, Woodman SE, Rimm DL, Kirkwood JM, Kluger HM, Schuchter LM, Lee SJ, Flaherty KT, Nathanson KL. Copy number changes are associated with response to treatment with carboplatin, paclitaxel, and sorafenib in melanoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26307133 DOI: 10.1158/1078-0432.CCR-15-1162  0.64
2015 Glitza IC, Haymaker C, Bernatchez C, Vence LM, Rohlfs ML, Richard J, Lacey C, Mansaray R, Fulbright OJ, Ramachandran R, Toth C, Wardell S, Woodman SE, Patel S, Hwu WJ, et al. Intrathecal administration of tumor-infiltrating lymphocytes is well tolerated in a patient with leptomeningeal disease from metastatic melanoma: A case report. Cancer Immunology Research. PMID 26216417 DOI: 10.1158/2326-6066.CIR-15-0071  0.64
2015 Capparelli C, Rosenbaum S, Berman-Booty LD, Salhi A, Gaborit N, Zhan T, Chervoneva I, Roszik J, Woodman SE, Davies MA, Setiady YY, Osman I, Yarden Y, Aplin AE. ErbB3-ErbB2 Complexes as a Therapeutic Target in a Subset of Wild-type BRAF/NRAS Cutaneous Melanomas. Cancer Research. 75: 3554-67. PMID 26206558 DOI: 10.1158/0008-5472.CAN-14-2959  0.64
2015 Tetzlaff MT, Pattanaprichakul P, Wargo J, Fox PS, Patel KP, Estrella JS, Broaddus RR, Williams MD, Davies MA, Routbort MJ, Lazar AJ, Woodman SE, Hwu WJ, Gershenwald JE, Prieto VG, et al. Utility of BRAF V600E Immunohistochemistry Expression Pattern as a Surrogate of BRAF Mutation Status in 154 Patients with Advanced Melanoma. Human Pathology. 46: 1101-10. PMID 26058727 DOI: 10.1016/j.humpath.2015.04.012  0.64
2015 Yu X, Ambrosini G, Roszik J, Eterovic AK, Stempke-Hale K, Seftor EA, Chattopadhyay C, Grimm E, Carvajal RD, Hendrix MJ, Hodi FS, Schwartz GK, Woodman SE. Genetic analysis of the 'uveal melanoma' C918 cell line reveals atypical BRAF and common KRAS mutations and single tandem repeat profile identical to the cutaneous melanoma C8161 cell line. Pigment Cell & Melanoma Research. 28: 357-9. PMID 25515650 DOI: 10.1111/pcmr.12345  0.64
2015 Siroy AE, Boland GM, Milton DR, Roszik J, Frankian S, Malke J, Haydu L, Prieto VG, Tetzlaff M, Ivan D, Wang WL, Torres-Cabala C, Curry J, Roy-Chowdhuri S, Broaddus R, ... ... Woodman SE, et al. Beyond BRAF(V600): clinical mutation panel testing by next-generation sequencing in advanced melanoma. The Journal of Investigative Dermatology. 135: 508-15. PMID 25148578 DOI: 10.1038/jid.2014.366  0.64
2014 Roszik J, Woodman SE. HotSpotter: efficient visualization of driver mutations. Bmc Genomics. 15: 1044. PMID 25435088 DOI: 10.1186/1471-2164-15-1044  0.64
2014 Peng G, Woodman SE, Mills GB. RADical response puts an exceptional responder in CHKmate: a synthetic lethal curative response to DNA-damaging chemotherapy? Cancer Discovery. 4: 988-90. PMID 25185187 DOI: 10.1158/2159-8290.CD-14-0738  0.64
2014 Alrwas A, Papadopoulos NE, Cain S, Patel SP, Kim KB, Deburr TL, Bassett R, Hwu WJ, Bedikian AY, Davies MA, Woodman SE, Hwu P. Phase I trial of biochemotherapy with cisplatin, temozolomide, and dose escalation of nab-paclitaxel combined with interleukin-2 and interferon-α in patients with metastatic melanoma. Melanoma Research. 24: 342-8. PMID 24743052 DOI: 10.1097/CMR.0000000000000062  0.64
2014 Chattopadhyay C, Grimm EA, Woodman SE. Simultaneous inhibition of the HGF/MET and Erk1/2 pathways affect uveal melanoma cell growth and migration. Plos One. 9: e83957. PMID 24551032 DOI: 10.1371/journal.pone.0083957  0.64
2013 Griewank KG, Westekemper H, Murali R, Mach M, Schilling B, Wiesner T, Schimming T, Livingstone E, Sucker A, Grabellus F, Metz C, Süsskind D, Hillen U, Speicher MR, Woodman SE, et al. Conjunctival melanomas harbor BRAF and NRAS mutations and copy number changes similar to cutaneous and mucosal melanomas. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 3143-52. PMID 23633454 DOI: 10.1158/1078-0432.CCR-13-0163  0.64
2013 Liu C, Peng W, Xu C, Lou Y, Zhang M, Wargo JA, Chen JQ, Li HS, Watowich SS, Yang Y, Tompers Frederick D, Cooper ZA, Mbofung RM, Whittington M, Flaherty KT, ... Woodman SE, et al. BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 393-403. PMID 23204132 DOI: 10.1158/1078-0432.CCR-12-1626  0.64
2012 Yang Y, Liu C, Peng W, Lizée G, Overwijk WW, Liu Y, Woodman SE, Hwu P. Antitumor T-cell responses contribute to the effects of dasatinib on c-KIT mutant murine mastocytoma and are potentiated by anti-OX40. Blood. 120: 4533-43. PMID 22936666 DOI: 10.1182/blood-2012-02-407163  0.64
2012 Kim J, Lazar AJ, Davies MA, Homsi J, Papadopoulos NE, Hwu WJ, Bedikian AY, Woodman SE, Patel SP, Hwu P, Kim KB. BRAF, NRAS and KIT sequencing analysis of spindle cell melanoma. Journal of Cutaneous Pathology. 39: 821-5. PMID 22809251 DOI: 10.1111/j.1600-0560.2012.01950.x  0.64
2012 Khalili JS, Yu X, Wang J, Hayes BC, Davies MA, Lizee G, Esmaeli B, Woodman SE. Combination small molecule MEK and PI3K inhibition enhances uveal melanoma cell death in a mutant GNAQ- and GNA11-dependent manner. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 4345-55. PMID 22733540 DOI: 10.1158/1078-0432.CCR-11-3227  0.64
2012 Woodman SE. Metastatic uveal melanoma: biology and emerging treatments. Cancer Journal (Sudbury, Mass.). 18: 148-52. PMID 22453016 DOI: 10.1097/PPO.0b013e31824bd256  0.64
2012 Woodman SE, Lazar AJ, Aldape KD, Davies MA. New strategies in melanoma: molecular testing in advanced disease. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 1195-200. PMID 22275506 DOI: 10.1158/1078-0432.CCR-11-2317  0.64
2012 Griewank KG, Yu X, Khalili J, Sozen MM, Stempke-Hale K, Bernatchez C, Wardell S, Bastian BC, Woodman SE. Genetic and molecular characterization of uveal melanoma cell lines Pigment Cell and Melanoma Research. 25: 182-187. PMID 22236444 DOI: 10.1111/j.1755-148X.2012.00971.x  0.64
2012 Deng W, Vashisht Gopal YN, Scott A, Chen G, Woodman SE, Davies MA. Role and therapeutic potential of PI3K-mTOR signaling in de novo resistance to BRAF inhibition Pigment Cell and Melanoma Research. 25: 248-258. PMID 22171948 DOI: 10.1111/j.1755-148X.2011.00950.x  0.64
2012 Woodman SE. BAP1tism of a tumor suppressor. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 323-5. PMID 22140212 DOI: 10.1158/1078-0432.CCR-11-2870  0.64
2011 Patel SP, Woodman SE. Profile of ipilimumab and its role in the treatment of metastatic melanoma. Drug Design, Development and Therapy. 5: 489-95. PMID 22267918 DOI: 10.2147/DDDT.S10945  0.64
2010 Woodman SE, Mills GB. Are oncogenes sufficient to cause human cancer? Proceedings of the National Academy of Sciences of the United States of America. 107: 20599-600. PMID 21084639 DOI: 10.1073/pnas.1015563107  0.64
2010 Gopal YN, Deng W, Woodman SE, Komurov K, Ram P, Smith PD, Davies MA. Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells. Cancer Research. 70: 8736-47. PMID 20959481 DOI: 10.1158/0008-5472.CAN-10-0902  0.64
2010 Woodman SE, Davies MA. Targeting KIT in melanoma: a paradigm of molecular medicine and targeted therapeutics. Biochemical Pharmacology. 80: 568-74. PMID 20457136 DOI: 10.1016/j.bcp.2010.04.032  0.64
2009 Davies MA, Stemke-Hale K, Lin E, Tellez C, Deng W, Gopal YN, Woodman SE, Calderone TC, Ju Z, Lazar AJ, Prieto VG, Aldape K, Mills GB, Gershenwald JE. Integrated Molecular and Clinical Analysis of AKT Activation in Metastatic Melanoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 7538-7546. PMID 19996208 DOI: 10.1158/1078-0432.CCR-09-1985  0.64
2009 Woodman SE, Trent JC, Stemke-Hale K, Lazar AJ, Pricl S, Pavan GM, Fermeglia M, Gopal YN, Yang D, Podoloff DA, Ivan D, Kim KB, Papadopoulos N, Hwu P, Mills GB, et al. Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates. Molecular Cancer Therapeutics. 8: 2079-85. PMID 19671763 DOI: 10.1158/1535-7163.MCT-09-0459  0.64
2008 Quintás-Cardama A, Lazar AJ, Woodman SE, Kim K, Ross M, Hwu P. Complete response of stage IV anal mucosal melanoma expressing KIT Val560Asp to the multikinase inhibitor sorafenib. Nature Clinical Practice. Oncology. 5: 737-40. PMID 18936790 DOI: 10.1038/ncponc1251  0.64
2005 De Souza AP, Cohen AW, Park DS, Woodman SE, Tang B, Gutstein DE, Factor SM, Tanowitz HB, Lisanti MP, Jelicks LA. MR imaging of caveolin gene-specific alterations in right ventricular wall thickness. Magnetic Resonance Imaging. 23: 61-8. PMID 15733789 DOI: 10.1016/j.mri.2004.11.011  0.64
2004 Woodman SE, Sotgia F, Galbiati F, Minetti C, Lisanti MP. Caveolinopathies: mutations in caveolin-3 cause four distinct autosomal dominant muscle diseases. Neurology. 62: 538-43. PMID 14981167  0.64
2004 Woodman SE, Cheung MW, Tarr M, North AC, Schubert W, Lagaud G, Marks CB, Russell RG, Hassan GS, Factor SM, Christ GJ, Lisanti MP. Urogenital alterations in aged male caveolin-1 knockout mice. The Journal of Urology. 171: 950-7. PMID 14713860 DOI: 10.1097/01.ju.0000105102.72295.b8  0.64
2003 Sotgia F, Bonuccelli G, Minetti C, Woodman SE, Capozza F, Kemp RG, Scherer PE, Lisanti MP. Phosphofructokinase muscle-specific isoform requires caveolin-3 expression for plasma membrane recruitment and caveolar targeting: implications for the pathogenesis of caveolin-related muscle diseases. The American Journal of Pathology. 163: 2619-34. PMID 14633633 DOI: 10.1016/S0002-9440(10)63616-4  0.64
2003 Bonuccelli G, Sotgia F, Schubert W, Park DS, Frank PG, Woodman SE, Insabato L, Cammer M, Minetti C, Lisanti MP. Proteasome inhibitor (MG-132) treatment of mdx mice rescues the expression and membrane localization of dystrophin and dystrophin-associated proteins. The American Journal of Pathology. 163: 1663-75. PMID 14507673 DOI: 10.1016/S0002-9440(10)63523-7  0.64
2003 Sotgia F, Woodman SE, Bonuccelli G, Capozza F, Minetti C, Scherer PE, Lisanti MP. Phenotypic behavior of caveolin-3 R26Q, a mutant associated with hyperCKemia, distal myopathy, and rippling muscle disease. American Journal of Physiology. Cell Physiology. 285: C1150-60. PMID 12839838 DOI: 10.1152/ajpcell.00166.2003  0.64
2003 Woodman SE, Ashton AW, Schubert W, Lee H, Williams TM, Medina FA, Wyckoff JB, Combs TP, Lisanti MP. Caveolin-1 knockout mice show an impaired angiogenic response to exogenous stimuli. The American Journal of Pathology. 162: 2059-68. PMID 12759260 DOI: 10.1016/S0002-9440(10)64337-4  0.64
2003 Frank PG, Woodman SE, Park DS, Lisanti MP. Caveolin, caveolae, and endothelial cell function. Arteriosclerosis, Thrombosis, and Vascular Biology. 23: 1161-8. PMID 12689915 DOI: 10.1161/01.ATV.0000070546.16946.3A  0.64
2003 Cohen AW, Park DS, Woodman SE, Williams TM, Chandra M, Shirani J, Pereira de Souza A, Kitsis RN, Russell RG, Weiss LM, Tang B, Jelicks LA, Factor SM, Shtutin V, Tanowitz HB, et al. Caveolin-1 null mice develop cardiac hypertrophy with hyperactivation of p42/44 MAP kinase in cardiac fibroblasts. American Journal of Physiology. Cell Physiology. 284: C457-74. PMID 12388077 DOI: 10.1152/ajpcell.00380.2002  0.64
2002 Razani B, Woodman SE, Lisanti MP. Caveolae: from cell biology to animal physiology. Pharmacological Reviews. 54: 431-67. PMID 12223531 DOI: 10.1124/pr.54.3.431  0.64
2002 Schubert W, Frank PG, Woodman SE, Hyogo H, Cohen DE, Chow CW, Lisanti MP. Microvascular hyperpermeability in caveolin-1 (-/-) knock-out mice. Treatment with a specific nitric-oxide synthase inhibitor, L-NAME, restores normal microvascular permeability in Cav-1 null mice. The Journal of Biological Chemistry. 277: 40091-8. PMID 12167625 DOI: 10.1074/jbc.M205948200  0.64
2002 Woodman SE, Park DS, Cohen AW, Cheung MW, Chandra M, Shirani J, Tang B, Jelicks LA, Kitsis RN, Christ GJ, Factor SM, Tanowitz HB, Lisanti MP. Caveolin-3 knock-out mice develop a progressive cardiomyopathy and show hyperactivation of the p42/44 MAPK cascade. The Journal of Biological Chemistry. 277: 38988-97. PMID 12138167 DOI: 10.1074/jbc.M205511200  0.64
2002 Park DS, Woodman SE, Schubert W, Cohen AW, Frank PG, Chandra M, Shirani J, Razani B, Tang B, Jelicks LA, Factor SM, Weiss LM, Tanowitz HB, Lisanti MP. Caveolin-1/3 double-knockout mice are viable, but lack both muscle and non-muscle caveolae, and develop a severe cardiomyopathic phenotype. The American Journal of Pathology. 160: 2207-17. PMID 12057923 DOI: 10.1016/S0002-9440(10)61168-6  0.64
2002 Woodman SE, Schlegel A, Cohen AW, Lisanti MP. Mutational analysis identifies a short atypical membrane attachment sequence (KYWFYR) within caveolin-1. Biochemistry. 41: 3790-5. PMID 11888297 DOI: 10.1021/bi0120751  0.64
2001 Lee H, Woodman SE, Engelman JA, Volonté D, Galbiati F, Kaufman HL, Lublin DM, Lisanti MP. Palmitoylation of caveolin-1 at a single site (Cys-156) controls its coupling to the c-Src tyrosine kinase: targeting of dually acylated molecules (GPI-linked, transmembrane, or cytoplasmic) to caveolae effectively uncouples c-Src and caveolin-1 (TYR-14). The Journal of Biological Chemistry. 276: 35150-8. PMID 11451957 DOI: 10.1074/jbc.M104530200  0.64
2000 Wu DT, Woodman SE, Weiss JM, McManus CM, D'Aversa TG, Hesselgesser J, Major EO, Nath A, Berman JW. Mechanisms of leukocyte trafficking into the CNS. Journal of Neurovirology. 6: S82-5. PMID 10871769  0.64
2000 McManus CM, Weidenheim K, Woodman SE, Nunez J, Hesselgesser J, Nath A, Berman JW. Chemokine and chemokine-receptor expression in human glial elements: Induction by the HIV protein, Tat, and chemokine autoregulation American Journal of Pathology. 156: 1441-1453. PMID 10751368  0.64
1999 Woodman SE, Benveniste EN, Nath A, Berman JW. Human immunodeficiency virus type 1 TAT protein induces adhesion molecule expression in astrocytes. Journal of Neurovirology. 5: 678-84. PMID 10602408  0.64
Low-probability matches
2018 Forget MA, Haymaker C, Hess KR, Meng YJ, Creasy C, Karpinets TV, Fulbright OJ, Roszik J, Woodman SE, Kim YU, Sakellariou-Thompson D, Bhatta A, Wahl A, Flores E, Thorsen ST, et al. Prospective analysis of adoptive TIL therapy in patients with metastatic melanoma: response, impact of anti-CTLA4, and biomarkers to predict clinical outcome. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29848573 DOI: 10.1158/1078-0432.CCR-17-3649  0.04
2018 Cascone T, McKenzie JA, Mbofung RM, Punt S, Wang Z, Xu C, Williams LJ, Wang Z, Bristow CA, Carugo A, Peoples MD, Li L, Karpinets T, Huang L, Malu S, ... ... Woodman SE, et al. Increased Tumor Glycolysis Characterizes Immune Resistance to Adoptive T Cell Therapy. Cell Metabolism. PMID 29628419 DOI: 10.1016/j.cmet.2018.02.024  0.04
2018 Huang L, Malu S, McKenzie JA, Andrews MC, Talukder AH, Tieu T, Karpinets TV, Haymaker C, Forget MA, Williams LJ, Wang Z, Mbofung R, Wang ZQ, Davis RE, Lo RS, ... ... Woodman SE, et al. The RNA-binding protein MEX3B mediates resistance to cancer immunotherapy by downregulating HLA-A expression. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29496759 DOI: 10.1158/1078-0432.CCR-17-2483  0.04
2018 Glitza IC, Rohlfs M, Guha-Thakurta N, Bassett RL, Bernatchez C, Diab A, Woodman SE, Yee C, Amaria RN, Patel SP, Tawbi H, Wong M, Hwu WJ, Hwu P, Heimberger A, et al. Retrospective review of metastatic melanoma patients with leptomeningeal disease treated with intrathecal interleukin-2. Esmo Open. 3: e000283. PMID 29387478 DOI: 10.1136/esmoopen-2017-000283  0.04
2018 Amaria RN, Prieto PA, Tetzlaff MT, Reuben A, Andrews MC, Ross MI, Glitza IC, Cormier J, Hwu WJ, Tawbi HA, Patel SP, Lee JE, Gershenwald JE, Spencer CN, Gopalakrishnan V, ... ... Woodman SE, et al. Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial. The Lancet. Oncology. PMID 29361468 DOI: 10.1016/S1470-2045(18)30015-9  0.04
2017 Reuben A, Spencer CN, Prieto PA, Gopalakrishnan V, Reddy SM, Miller JP, Mao X, De Macedo MP, Chen J, Song X, Jiang H, Chen PL, Beird HC, Garber HR, Roh W, ... ... Woodman SE, et al. Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma. Npj Genomic Medicine. 2. PMID 28819565 DOI: 10.1038/s41525-017-0013-8  0.04
2017 Roh W, Chen PL, Reuben A, Spencer CN, Prieto PA, Miller JP, Gopalakrishnan V, Wang F, Cooper ZA, Reddy SM, Gumbs C, Little L, Chang Q, Chen WS, Wani K, ... ... Woodman SE, et al. Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance. Science Translational Medicine. 9. PMID 28251903 DOI: 10.1126/scitranslmed.aah3560  0.04
2016 Kim DW, Haydu LE, Joon AY, Bassett RL, Siroy AE, Tetzlaff MT, Routbort MJ, Amaria RN, Wargo JA, McQuade JL, Kemnade J, Hwu P, Woodman SE, Roszik J, Kim KB, et al. Clinicopathological features and clinical outcomes associated with TP53 and BRAF(N)(on-)(V)(600) mutations in cutaneous melanoma patients. Cancer. PMID 27911979 DOI: 10.1002/cncr.30463  0.04
2016 Roszik J, Haydu LE, Hess KR, Oba J, Joon AY, Siroy AE, Karpinets TV, Stingo FC, Baladandayuthapani V, Tetzlaff MT, Wargo JA, Chen K, Forget MA, Haymaker CL, Chen JQ, ... ... Woodman SE, et al. Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set. Bmc Medicine. 14: 168. PMID 27776519 DOI: 10.1186/s12916-016-0705-4  0.04
2016 Cooper ZA, Reuben A, Spencer CN, Prieto PA, Austin-Breneman JL, Jiang H, Haymaker C, Gopalakrishnan V, Tetzlaff MT, Frederick DT, Sullivan RJ, Amaria RN, Patel SP, Hwu P, Woodman SE, et al. Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma. Oncoimmunology. 5: e1136044. PMID 27141370 DOI: 10.1080/2162402X.2015.1136044  0.04
2019 Chattopadhyay C, Oba J, Roszik J, Marszalek JR, Chen K, Qi Y, Eterovic K, Robertson AG, Burks JK, McCannel TA, Grimm EA, Woodman SE. Elevated Endogenous SDHA Drives Pathological Metabolism in Highly Metastatic Uveal Melanoma. Investigative Ophthalmology & Visual Science. 60: 4187-4195. PMID 31596927 DOI: 10.1167/iovs.19-28082  0.01
2019 Zeng J, Johnson A, Shufean MA, Kahle M, Yang D, Woodman SE, Vu T, Moorthy S, Holla V, Meric-Bernstam F. Operationalization of Next-Generation Sequencing and Decision Support for Precision Oncology. Jco Clinical Cancer Informatics. 3: 1-12. PMID 31550176 DOI: 10.1200/CCI.19.00089  0.01
2019 McKean M, Oba J, Ma J, Roth KG, Wang WL, Macedo MP, Carapeto FCL, Haydu LE, Siroy AE, Vo P, Hong DS, Eterovic AK, Patel KP, Bassett RL, Grimm EA, ... ... Woodman SE, et al. Tyrosine Kinase Inhibitor and Immune Checkpoint Inhibitor Responses in KIT-Mutant Metastatic Melanoma. The Journal of Investigative Dermatology. 139: 728-731. PMID 30798855 DOI: 10.1016/j.jid.2018.10.009  0.01
2018 Oba J, Kim SH, Wang WL, Macedo MP, Carapeto F, McKean MA, Van Arnam J, Eterovic AK, Sen S, Kale CR, Yu X, Haymaker CL, Routbort M, Haydu LE, Bernatchez C, ... ... Woodman SE, et al. Targeting the HGF/MET Axis Counters Primary Resistance to KIT Inhibition in -Mutant Melanoma. Jco Precision Oncology. 2018. PMID 30094412  0.01
2018 Chen L, Diao L, Yang Y, Yi X, Rodriguez BL, Li Y, Villalobos PA, Cascone T, Liu X, Tan L, Lorenzi PL, Huang A, Zhao Q, Peng D, Fradette J, ... ... Woodman SE, et al. CD38-mediated immunosuppression as a mechanism of tumor cell escape from PD-1/PD-L1 blockade. Cancer Discovery. PMID 30012853 DOI: 10.1158/2159-8290.CD-17-1033  0.01
2018 Robertson AG, Shih J, Yau C, Gibb EA, Oba J, Mungall KL, Hess JM, Uzunangelov V, Walter V, Danilova L, Lichtenberg TM, Kucherlapati M, Kimes PK, Tang M, Penson A, ... ... Woodman SE, et al. Integrative Analysis Identifies Four Molecular and Clinical Subsets in Uveal Melanoma. Cancer Cell. 33: 151. PMID 29316429 DOI: 10.1016/j.ccell.2017.12.013  0.01
2017 Robertson AG, Shih J, Yau C, Gibb EA, Oba J, Mungall KL, Hess JM, Uzunangelov V, Walter V, Danilova L, Lichtenberg TM, Kucherlapati M, Kimes PK, Tang M, Penson A, ... ... Woodman SE, et al. Integrative Analysis Identifies Four Molecular and Clinical Subsets in Uveal Melanoma. Cancer Cell. 32: 204-220.e15. PMID 28810145 DOI: 10.1016/j.ccell.2017.07.003  0.01
2017 Park J, Talukder AH, Lim S, Kim K, Pan K, Melendez B, Bradley SD, Jackson K, Khalili JS, Wang J, Creasy C, Pan BF, Woodman SE, Bernatchez C, Hawke D, et al. SLC45A2: A melanoma antigen with high tumor selectivity and reduced potential for autoimmune toxicity. Cancer Immunology Research. PMID 28630054 DOI: 10.1158/2326-6066.CIR-17-0051  0.01
2017 Johnson CP, Kim IK, Esmaeli B, Amin-Mansour A, Treacy DJ, Carter SL, Hodis E, Wagle N, Seepo S, Yu X, Lane AM, Gragoudas ES, Vazquez F, Nickerson E, Cibulskis K, ... ... Woodman SE, et al. Systematic genomic and translational efficiency studies of uveal melanoma. Plos One. 12: e0178189. PMID 28594900 DOI: 10.1371/journal.pone.0178189  0.01
2017 Jager MJ, Dogrusöz M, Woodman SE. Uveal Melanoma: Identifying Immunological and Chemotherapeutic Targets to Treat Metastases. Asia-Pacific Journal of Ophthalmology (Philadelphia, Pa.). 6: 179-185. PMID 28399339 DOI: 10.22608/APO.201782  0.01
2016 Chattopadhyay C, Kim DW, Gombos DS, Oba J, Qin Y, Williams MD, Esmaeli B, Grimm EA, Wargo JA, Woodman SE, Patel SP. Uveal melanoma: From diagnosis to treatment and the science in between. Cancer. PMID 26991400 DOI: 10.1002/cncr.29727  0.01
2016 Ekmekcioglu S, Davies MA, Tanese K, Roszik J, Shin-Sim M, Bassett RL, Milton DR, Woodman SE, Prieto VG, Gershenwald JE, Morton DL, Hoon DS, Grimm EA. Inflammatory Marker Testing Identifies CD74 Expression in Melanoma Tumor Cells, and its Expression Associates with Favorable Survival for Stage III Melanoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26783288 DOI: 10.1158/1078-0432.CCR-15-2226  0.01
2015 Peng W, Chen JQ, Liu C, Malu S, Creasy C, Tetzlaff MT, Xu C, McKenzie JA, Zhang C, Liang X, Williams LJ, Deng W, Chen G, Mbofung R, Lazar AJ, ... ... Woodman SE, et al. Loss of PTEN promotes resistance to T cell-mediated immunotherapy. Cancer Discovery. PMID 26645196 DOI: 10.1158/2159-8290.CD-15-0283  0.01
Hide low-probability matches.